One of the most extensively studied classes of anti-inflammatory therapies in IBD is the anti-TNF-α agents, which indirectly impact angiogenesis by modulating the immune response and reducing cytokine-driven inflammation. The gene discussed is TNF; the disease is inflammatory bowel disease.